Phase II study of vindesine in patients with advanced breast cancer. 1982

B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning

Vindesine, a new vinca alkaloid, was administered to 20 patients with advanced refractory breast cancer in a phase II trial. The drug was given at a dose of 3 mg/m2 by iv bolus each week for 6 consecutive weeks, and responding patients were maintained on a dose of 4 mg/m2 every 2 weeks. Nineteen patients were evaluable for disease response; partial remissions were obtained in five patients, for a response rate of 26%. Leukopenia was the major dose-limiting toxic reaction, but most patients were able to tolerate this schedule without difficulty. Neurotoxicity was mild and did not require dose reduction.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1980, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1981, Cancer clinical trials,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1981, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
March 1983, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
May 1983, European journal of cancer & clinical oncology,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
December 1995, European journal of cancer (Oxford, England : 1990),
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1983, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
March 1984, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1979, Cancer treatment reports,
B K Walker, and P C Raich, and J Fontana, and V P Subramanian, and J S Rogers, and J A Knost, and B Denning
January 1981, Cancer treatment reports,
Copied contents to your clipboard!